Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PMGC Holdings Inc. - Common Stock (NQ:ELAB)

2.180 -0.130 (-5.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PMGC Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
12 Consumer Staples Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
ELAB Stock Earnings: Elevai Labs Reported Results for Q2 2024 ↗
Elevai Labs just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
ELAB Stock Earnings: Elevai Labs Reported Results for Q1 2024 ↗
Elevai Labs just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ELAB Stock Earnings: Elevai Labs Reported Results for Q4 2023 ↗
Elevai Labs just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Top 4 Risk Off Stocks You'll Regret Missing In July ↗
 
Via Benzinga
News headline image
Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries 
Via News Direct
News headline image
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
12 Consumer Staples Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
12 Consumer Staples Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers 
From Elevai Labs Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.